Adam Walter‐Croneck

Medical University of Lublin — Poland

Medicine · Health Sciences

15h-index2.7kcitations65works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(35), Peptidase Inhibition and Analysis(11), Chronic Lymphocytic Leukemia Research(10), Protein Degradation and Inhibitors(9), Chronic Myeloid Leukemia Treatments(8)

Publications64 total

A Stepwise Screening Protocol for Multiple Myeloma
Journal of Clinical Medicine·2023· 2 citedOpen Access
Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial
The Lancet Oncology·2023· 69 citedOpen Access
S175: ATLAS: A PHASE 3 RANDOMIZED TRIAL OF CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE VERSUS LENALIDOMIDE ALONE AFTER STEM-CELL TRANSPLANT FOR MULTIPLE MYELOMA
HemaSphere·2022· 1 citedOpen Access
Antimicrobial prophylaxis in adults and children undergoing hematopoietic cell transplantation: 2021 Polish recommendations
Acta Haematologica Polonica·2021· 6 citedOpen Access
Protective environment in hematopoietic cell transplantation centers: results of a survey of the Polish Federation of Bone Marrow Transplant Centers
Acta Haematologica Polonica·2021Open Access
Differential Function of a Novel Population of the CD19+CD24hiCD38hi Bregs in Psoriasis and Multiple Myeloma
Cells·2021· 12 citedOpen Access
Antimicrobial prophylaxis in patients after hematopoietic cell transplantation: results of a survey of the Polish Federation of Bone Marrow Transplant Centers
Acta Haematologica Polonica·2020· 9 citedOpen Access
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study
Blood Cancer Journal·2020· 151 citedOpen Access
Elotuzumab plus lenalidomide/dexamethasone for relapsed/refractory multiple myeloma: Final overall survival results from the phase 3 ELOQUENT-2 trial
Clinical Lymphoma Myeloma & Leukemia·2019· 8 cited
Wyzwania wczesnej diagnostyki szpiczaka plazmocytowego – algorytm diagnostyczny
Acta Haematologica Polonica·2019· 2 citedOpen Access
IMPACT OF SURGERY TYPE ON THE OVERALL SURVIVAL TIME OF PATIENTS WITH PRIMARY BRAIN LYMPHOMA
Hematological Oncology·2019
Efficacy of daratumumab monotherapy in real-world heavily pretreated patients with relapsed or refractory multiple myeloma
Advances in Medical Sciences·2019· 24 cited
Zalecenia Polskiej Grupy Szpiczakowej dotyczące rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2018/2019
Acta Haematologica Polonica·2018· 22 citedOpen Access
Extended 5-Year Follow-Up of the Phase 3 ELOQUENT-2 Study of Elotuzumab Plus Lenalidomide/Dexamethasone (ELd) Versus Ld in Relapsed/Refractory Multiple Myeloma (RRMM)
Clinical Lymphoma Myeloma & Leukemia·2018· 1 cited
Extended 5-y follow-up (FU) of phase 3 ELOQUENT-2 study of elotuzumab + lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM).
Journal of Clinical Oncology·2018· 11 cited
Real-life experience with bortezomib-based regimens in elderly comorbid patients with newly diagnosed multiple myeloma – Polish retrospective multicenter analysis
Polskie Archiwum Medycyny Wewnętrznej·2017· 7 citedOpen Access
Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: <scp>ELOQUENT</scp>‐2 follow‐up and <i>post‐hoc</i> analyses on progression‐free survival and tumour growth
British Journal of Haematology·2017· 131 citedOpen Access
Phase 3 ELOQUENT-2 study: Extended four year follow-up (FU) of elotuzumab plus lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM).
Journal of Clinical Oncology·2017· 9 cited
Zalecenia Polskiej Grupy Szpiczakowej dotyczące rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2017
Acta Haematologica Polonica·2017· 13 cited
Zalecenia Polskiej Grupy Szpiczakowej dotyczące rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2016
Acta Haematologica Polonica·2016· 9 cited
page 1 of 4Next →

Frequent Co-authors

Anna Dmoszyńska(28), Krzysztof Giannopoulos(13), Lidia Usnarska‐Zubkiewicz(13), Agnieszka Druzd‐Sitek(12), Sebastian Grosicki(10), Dominik Dytfeld(10), Krzysztof Jamroziak(10), Sagar Lonial(9), Meletios Α. Dimopoulos(9), Darrell White(9), Ivan Špıčka(9), Philippe Moreau(9), María‐Victoria Mateos(9), Andrew R. Belch(9), Donna Reece(9), Meral Beksaç(9), Anil Singhal(9), Paul G. Richardson(9), Artur Jurczyszyn(9), Jesús F. San Miguel(8)